FABP4 and atherosclerosis: The inhibition of FABP4 can improve type 2 diabetes mellitus and atherosclerosis in mouse model, and elevated circulating FABP4 levels are associated with obesity, metabolic disease, and cardiac dysfunction in humans [12].